Mark G. Anderson

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 1.9K citations · Full text

Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737

Stephen K. Tahir, Xiufen Yang, Mark G. Anderson et al. · Cancer Research · 2007 · 301 citations

Sclc Cells, Medicine, Oncogenic Agent +14

Expression of VDR and CYP24A1 mRNA in human tumors

Mark G. Anderson, Masaki Nakane, Xiaoan Ruan et al. · Cancer Chemotherapy and Pharmacology · 2005 · 240 citations

Tumor Biology, Medicine, Cyp24a1 Mrna +5

Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: pathogenesis of infection in macaques

Dharam P. Sharma, M. Christine Zink, Mark G. Anderson et al. · Journal of Virology · 1992 · 176 citations · Full text

Viral Pathogenesis, Immunology, Simian Immunodeficiency Virus +16

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <i>MET</i> –Amplified and c-Met–Overexpressing Tumors, Irrespective of <i>MET</i> Pathway Dependence

Jieyi Wang, Mark G. Anderson, Anatol Oleksijew et al. · Clinical Cancer Research · 2016 · 127 citations · Full text